Published in Cancer Weekly, January 18th, 2005
Key investors in this financing included Zenkoku Hosho Co., Ltd., Softbank Investment Corp. (through its managed investment fund) and Kyorin Pharmaceutical Co., Ltd.
Y's Therapeutics has 5 projects in its portfolio. YSIL6 is a small molecule drug development project for treatment of rheumatoid arthritis and other inflammatory disorders. The molecule's modes of action include inhibition of TNF-a and IL-6 production in T-cells and macrophages and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.